GEA
SGMO

Glen Eagle Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Glen Eagle Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-255
Closed -$2.41K – 1003
2020
Q3 		$2.41K Hold
255
– – ﹤0.01% 781
2020
Q2 		$2.29K Hold
255
– – ﹤0.01% 748
2020
Q1 		$1.62K Hold
255
– – ﹤0.01% 723
2019
Q4 		$2.13K Hold
255
– – ﹤0.01% 771
2019
Q3 		$2.31K Hold
255
– – ﹤0.01% 702
2019
Q2 		$2.75K Buy
255
+130
+104% +$1.38K ﹤0.01% 672
2019
Q1 		$1.19K Hold
125
– – ﹤0.01% 691
2018
Q4 		$1.44K Hold
125
– – ﹤0.01% 652
2018
Q3 		$2.12K Buy
+125
New +$1.9K ﹤0.01% 628

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Glen Eagle Advisors's SGMO Position: Q4 2020 in Review

Glen Eagle Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2020, closing a stake of 255 shares — an estimated $2.41K sold.

Glen Eagle Advisors first reported a position in SGMO in Q3 2018 and held it in 9 quarters. The position peaked at $2.75K in Q2 2019. 223 funds tracked by Wall St. Rank hold SGMO as of Q4 2020.

  • Glen Eagle Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2020 after selling out during the quarter.
  • Glen Eagle Advisors sold 255 SANGAMO THERAPEUTICS INC shares in Q4 2020, an estimated $2.41K.
  • Glen Eagle Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q3 2018 and held it in 9 quarters.
  • Glen Eagle Advisors's SANGAMO THERAPEUTICS INC position peaked at $2.75K in Q2 2019.
  • 223 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2020.

Based on Glen Eagle Advisors's 13F filing for Q4 2020, filed 13 Aug 2024.